PH26391A - Method for treating gastrointestinal disorders - Google Patents

Method for treating gastrointestinal disorders Download PDF

Info

Publication number: PH26391A
Authority: PH; Philippines
Prior art keywords: compound; gastro; administered; alkyl; acyl
Prior art date: 1988-04-18

Application number

PH38516A

Other languages

English (en)

Inventor

Jaswant Singh Gidda

Herbert Andrew Kirst

David Wayne Robertson

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-04-18

Filing date

1989-04-17

Publication date

1992-07-02

1989-04-17 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1992-07-02 Publication of PH26391A publication Critical patent/PH26391A/en

Links

238000000034 method Methods 0.000 title claims description 21
208000018522 Gastrointestinal disease Diseases 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims description 64
150000003839 salts Chemical class 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 15
241001465754 Metazoa Species 0.000 claims description 10
238000011282 treatment Methods 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 7
-1 pydroxide Chemical class 0.000 claims description 6
125000002252 acyl group Chemical group 0.000 claims description 5
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
150000005676 cyclic carbonates Chemical class 0.000 claims description 5
208000017228 Gastrointestinal motility disease Diseases 0.000 claims description 4
150000004820 halides Chemical class 0.000 claims description 4
229910002651 NO3 Inorganic materials 0.000 claims description 3
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
125000001309 chloro group Chemical group Cl* 0.000 claims description 3
125000001153 fluoro group Chemical group F* 0.000 claims description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
125000003342 alkenyl group Chemical group 0.000 claims description 2
150000007942 carboxylates Chemical class 0.000 claims description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
208000028774 intestinal disease Diseases 0.000 claims 4
229910019142 PO4 Inorganic materials 0.000 claims 1
125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
150000008052 alkyl sulfonates Chemical class 0.000 claims 1
125000005228 aryl sulfonate group Chemical group 0.000 claims 1
125000004093 cyano group Chemical group *C#N 0.000 claims 1
230000008991 intestinal motility Effects 0.000 claims 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
239000010452 phosphate Substances 0.000 claims 1
125000001424 substituent group Chemical group 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
208000035475 disorder Diseases 0.000 description 7
230000000694 effects Effects 0.000 description 7
230000004899 motility Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
239000002253 acid Substances 0.000 description 5
229960003276 erythromycin Drugs 0.000 description 5
239000010410 layer Substances 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
229940125904 compound 1 Drugs 0.000 description 4
238000011161 development Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000000434 field desorption mass spectrometry Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000005176 gastrointestinal motility Effects 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
239000003120 macrolide antibiotic agent Substances 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
239000003826 tablet Substances 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
229940125782 compound 2 Drugs 0.000 description 3
210000001198 duodenum Anatomy 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
230000001330 gastroprokinetic effect Effects 0.000 description 3
239000002504 physiological saline solution Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
229960001866 silicon dioxide Drugs 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000032258 transport Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
229930003347 Atropine Natural products 0.000 description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
JFVYXJKGJMUGRG-KJPZRSJGSA-N Erythromycin a enol ether Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C2=C(C)C[C@](O2)(C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 JFVYXJKGJMUGRG-KJPZRSJGSA-N 0.000 description 2
KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
241000315040 Omura Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
230000003187 abdominal effect Effects 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
229960000396 atropine Drugs 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
230000001713 cholinergic effect Effects 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
230000002354 daily effect Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
229940041033 macrolides Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
229960004503 metoclopramide Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
239000003921 oil Substances 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000002953 preparative HPLC Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241001501536 Alethe Species 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
102100035342 Cysteine dioxygenase type 1 Human genes 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010051153 Diabetic gastroparesis Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101000737778 Homo sapiens Cysteine dioxygenase type 1 Proteins 0.000 description 1
206010021333 Ileus paralytic Diseases 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
241000282339 Mustela Species 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
206010030216 Oesophagitis Diseases 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000011280 coal tar Substances 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000037020 contractile activity Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
229940069331 cutar Drugs 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
208000006881 esophagitis Diseases 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
229960004667 ethyl cellulose Drugs 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
208000001288 gastroparesis Diseases 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
208000008384 ileus Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
150000002611 lead compounds Chemical class 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000003149 muscarinic antagonist Substances 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
230000001769 paralizing effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000002325 prokinetic agent Substances 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
210000001187 pylorus Anatomy 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
210000005070 sphincter Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000012360 testing method Methods 0.000 description 1
CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
229950010357 tetrodotoxin Drugs 0.000 description 1
CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000003643 water by type Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000009637 wintergreen oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

PH38516A 1988-04-18 1989-04-17 Method for treating gastrointestinal disorders PH26391A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/182,645 US4920102A (en)	1988-04-18	1988-04-18	Method for treating gastrointestinal disorders

Publications (1)

Publication Number	Publication Date
PH26391A true PH26391A (en)	1992-07-02

Family

ID=22669415

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH38516A PH26391A (en)	1988-04-18	1989-04-17	Method for treating gastrointestinal disorders

Country Status (22)

Country	Link
US (1)	US4920102A (da)
EP (1)	EP0349100B1 (da)
JP (1)	JPH0825882B2 (da)
KR (1)	KR970009580B1 (da)
CN (1)	CN1023017C (da)
AR (1)	AR244699A1 (da)
AT (1)	ATE139782T1 (da)
AU (1)	AU616746B2 (da)
CA (1)	CA1328257C (da)
DE (1)	DE68926728T2 (da)
DK (1)	DK183589A (da)
ES (1)	ES2088388T3 (da)
GR (1)	GR3020604T3 (da)
HU (1)	HU206365B (da)
IE (1)	IE72969B1 (da)
IL (1)	IL89996A (da)
MX (1)	MX15701A (da)
NZ (1)	NZ228768A (da)
PH (1)	PH26391A (da)
PT (1)	PT90293B (da)
RU (1)	RU2086560C1 (da)
ZA (1)	ZA892801B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5106961A (en) *	1987-05-26	1992-04-21	Eli Lilly And Company	Erythromycin ring-contracted derivatives
US5068221A (en) *	1989-05-09	1991-11-26	Mathias John R	Treatment of motility disorders with a gnrh analog
US5434136A (en) *	1990-12-14	1995-07-18	Mathias; John R.	Treatment of motility disorders with a GNRH analog
US5523418A (en) *	1991-04-09	1996-06-04	Abbott Laboratories	Macrocyclic lactam prokinetic agents
DK0579770T3 (da) *	1991-04-09	1996-11-04	Abbott Lab	Makrocycliske lactamprokinetika
DE4200145A1 (de)	1992-01-07	1993-07-08	Kali Chemie Pharma Gmbh	7,10-epoxy-oxacyclododecan-derivate, verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DK0623021T3 (da) *	1992-01-21	1999-02-08	Abbott Lab	4"-deoxyerythromycinderivater
US5470961A (en) *	1992-03-19	1995-11-28	Takeda Chemical Ind., Ltd.	14 and/or 15-hydroxy 6,9 hemiacetal erythromycin derivatives
FR2697524B1 (fr) *	1992-11-05	1994-12-23	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5712253A (en) *	1996-06-18	1998-01-27	Abbott Laboratories	Macrocyclic 13-membered ring derivatives of erythromycins A and B
DE19644195A1 (de) *	1996-10-24	1998-04-30	Solvay Pharm Gmbh	10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19805822B4 (de) *	1998-02-13	2009-02-05	Solvay Pharmaceuticals Gmbh	11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6165985A (en) *	1998-02-13	2000-12-26	Solvay Pharmaceuticals Gmbh	11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
US5972898A (en) *	1998-03-27	1999-10-26	Abbott Laboratories	3',3-N-bis-substituted macrolide LHRH antagonists
US5955440A (en) *	1998-03-27	1999-09-21	Abbott Laboratories	Macrolide LHRH antagonists
US6387885B1 (en)	1998-08-26	2002-05-14	Abbott Laboratories	3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6020521A (en) *	1998-08-26	2000-02-01	Abbott Laboratories	Macrolide LHRH antagonists
US6451806B2 (en)	1999-09-29	2002-09-17	Adolor Corporation	Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en)	1999-11-29	2002-10-22	Adolor Corporation	Methods for the treatment and prevention of ileus
ATE321770T1 (de) *	2000-08-17	2006-04-15	Kitasato Inst	Pseudoerythromycin-derivate
GB0123400D0 (en) *	2001-09-28	2001-11-21	Novartis Ag	Organic compounds
RU2202351C1 (ru) *	2001-11-29	2003-04-20	Дальневосточный государственный медицинский университет	Способ коррекции гастропареза после органосохраняющих операций на желудке
US20040067896A1 (en) *	2002-07-25	2004-04-08	The Kitasato Institute	Novel pseudoerythromycin derivatives
WO2004039823A1 (ja) *	2002-10-29	2004-05-13	The Kitasato Institute	抗真菌活性増強作用を有する新規マクロライド誘導体
DK1633774T3 (da)	2003-06-18	2010-05-25	Tranzyme Pharma Inc	Makrocykliske motilinreceptorantagonister
JP2009518396A (ja) *	2005-12-08	2009-05-07	ファイザー・インク	エリスロマイシン化合物の３’−ジメチルアミノ基を脱メチルする方法
EP2431380A3 (en)	2006-09-11	2013-07-03	Tranzyme Pharma, Inc.	Macrocyclic antagonist of the motilin receptor for treatment of gastrointestinal dysmotility disorders
US20080287371A1 (en) *	2007-05-17	2008-11-20	Tranzyme Pharma Inc.	Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex
FR2995605B1 (fr) *	2012-09-18	2014-09-19	Sanofi Sa	Derives de macrolides, leur preparation et leur application therapeutique.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4547491A (en) *	1984-07-18	1985-10-15	Merck & Co., Inc.	C-8A-Oxo-avermectin and milbemycin derivatives, pharmaceutical compositions and method of use
JPS6187625A (ja) *	1984-10-05	1986-05-06	Satoshi Omura	消化管収縮運動促進剤
DE3689758T2 (de) *	1985-08-31	1994-08-18	Kitasato Inst	Erythromycinderivat und Verfahren zu dessen Herstellung.
CA1321581C (en) *	1987-05-26	1993-08-24	Herbert A. Kirst	Ring-contracted macrolides

1988
- 1988-04-18 US US07/182,645 patent/US4920102A/en not_active Expired - Lifetime
1989
- 1989-04-17 HU HU891879A patent/HU206365B/hu not_active IP Right Cessation
- 1989-04-17 AU AU33107/89A patent/AU616746B2/en not_active Ceased
- 1989-04-17 CA CA000596863A patent/CA1328257C/en not_active Expired - Fee Related
- 1989-04-17 AR AR89313685A patent/AR244699A1/es active
- 1989-04-17 PT PT90293A patent/PT90293B/pt not_active IP Right Cessation
- 1989-04-17 ZA ZA892801A patent/ZA892801B/xx unknown
- 1989-04-17 IL IL8999689A patent/IL89996A/en not_active IP Right Cessation
- 1989-04-17 IE IE122489A patent/IE72969B1/en not_active IP Right Cessation
- 1989-04-17 DK DK183589A patent/DK183589A/da not_active Application Discontinuation
- 1989-04-17 PH PH38516A patent/PH26391A/en unknown
- 1989-04-17 NZ NZ228768A patent/NZ228768A/xx unknown
- 1989-04-18 ES ES89303813T patent/ES2088388T3/es not_active Expired - Lifetime
- 1989-04-18 KR KR89005088A patent/KR970009580B1/ko not_active Expired - Fee Related
- 1989-04-18 CN CN89102358A patent/CN1023017C/zh not_active Expired - Fee Related
- 1989-04-18 AT AT89303813T patent/ATE139782T1/de not_active IP Right Cessation
- 1989-04-18 MX MX1570189A patent/MX15701A/es unknown
- 1989-04-18 EP EP89303813A patent/EP0349100B1/en not_active Expired - Lifetime
- 1989-04-18 JP JP1099889A patent/JPH0825882B2/ja not_active Expired - Lifetime
- 1989-04-18 DE DE68926728T patent/DE68926728T2/de not_active Expired - Fee Related
1992
- 1992-08-04 RU SU925052262A patent/RU2086560C1/ru active
1996
- 1996-07-23 GR GR960401963T patent/GR3020604T3/el unknown

Also Published As

Publication number	Publication date
EP0349100A2 (en)	1990-01-03
IE891224L (en)	1989-10-18
CN1037517A (zh)	1989-11-29
AU3310789A (en)	1989-10-19
DE68926728T2 (de)	1996-11-28
HUT49625A (en)	1989-10-30
IE72969B1 (en)	1997-05-07
ZA892801B (en)	1990-12-28
AR244699A1 (es)	1993-11-30
KR970009580B1 (en)	1997-06-14
JPH0825882B2 (ja)	1996-03-13
JPH01311096A (ja)	1989-12-15
NZ228768A (en)	1990-10-26
AU616746B2 (en)	1991-11-07
RU2086560C1 (ru)	1997-08-10
DK183589A (da)	1989-10-19
CN1023017C (zh)	1993-12-08
EP0349100A3 (en)	1991-11-13
ATE139782T1 (de)	1996-07-15
IL89996A (en)	1994-08-26
DK183589D0 (da)	1989-04-17
ES2088388T3 (es)	1996-08-16
DE68926728D1 (de)	1996-08-01
PT90293A (pt)	1989-11-10
CA1328257C (en)	1994-04-05
MX15701A (es)	1993-11-01
HU206365B (en)	1992-10-28
IL89996A0 (en)	1989-12-15
US4920102A (en)	1990-04-24
EP0349100B1 (en)	1996-06-26
GR3020604T3 (en)	1996-10-31
KR900016220A (ko)	1990-11-12
PT90293B (pt)	1994-07-29

Publication	Publication Date	Title
PH26391A (en)	1992-07-02	Method for treating gastrointestinal disorders
DE69733369T2 (de)	2006-01-26	6-o-Substituierte Ketoliden mit antibakteriellen Wirking
US7323492B2 (en)	2008-01-29	7-pyrollyl 9-aminoacyl tetracycline compounds and methods of use thereof
JP5118973B2 (ja)	2013-01-16	新規ジヒドロシュードエリスロマイシン誘導体
EP0623021B1 (en)	1998-04-08	4''-deoxyerythromycin derivatives
DE69821009T2 (de)	2004-11-18	6,9-verbrückte erythromycin-derivate
AU663089B2 (en)	1995-09-28	Macrocyclic lactam prokinetic agents
HK1010054B (en)	1999-06-11	4"-deoxyerythromycin derivatives
US6440942B1 (en)	2002-08-27	14-membered macrolides derived from leucomycins
US6436906B1 (en)	2002-08-20	9-amino-14-membered macrolides derived from leucomycins
CA1323026C (en)	1993-10-12	Antibacterial 9-deoxo-9a-allyl and propargyl-9a-aza- 9a-homoerythromycin a derivatives
JP2922922B2 (ja)	1999-07-26	エリスロマイシン誘導体
EP1259923B1 (en)	2005-12-14	Anti-infective agents useful against mulitidrug-resistant strains of bacteria
JPH06247996A (ja)	1994-09-06	６−ｏ−メチルエリスロマイシンａ誘導体
AU2002246901A1 (en)	2002-08-12	14-membered macrolides derived from leucomycins
CZ2000811A3 (cs)	2000-06-14	6,9-můstkové erythromycinové deriváty a způsob jejich přípravy